{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87600"},{"groupId":"OG001","spread":"13","value":"100500"},{"groupId":"OG002","spread":"18","value":"90430"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"Total Carboplatin"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25","value":"55840"},{"groupId":"OG001","spread":"29","value":"52000"},{"groupId":"OG002","spread":"25","value":"52300"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"title":"Free Carboplatin"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"description":"AUCinf is the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"In chemotherapy phase, participants received paclitaxel Q3W (or QW on Days 1, 8 and 15), followed by carboplatin Q3W on Day 1 of each 21 day cycle for 6 cycles. During the maintenance phase, participants received avelumab Q2W on Days 1, 15 and 29 of each 42 day cycle.","id":"OG000","title":"PK: Chemotherapy Followed by Avelumab"},{"description":"In chemotherapy phase, participants received paclitaxel Q3W (or QW on Days 1, 8 and 15), followed by carboplatin Q3W along with avelumab Q3W on Day 1 of each 21 day cycle for 6 cycles. During the maintenance phase, participants received avelumab Q2W (on Days 1, 15 and 29 of each 42 day cycle).","id":"OG001","title":"PK: Chemotherapy + Avelumab Followed by Avelumab"},{"description":"In chemotherapy phase, participants received paclitaxel Q3W (or QW on Day 1, 8 and 15), followed by carboplatin Q3W on Day 1 of each 21 day cycle for 6 cycles.","id":"OG002","title":"PK: Chemotherapy Followed by Observation"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Carboplatin PK parameter analysis set included all participants who had received at least one dose of study drug and who had at least one of the PK parameters of interest for carboplatin. Here \"Overall number of participants analyzed\" signifies participants who had data available for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose and at 0.5, 1, 5, 6, 10, and 24 hours post carboplatin infusion on Day 1 of Cycle 2","title":"Chemotherapy Phase: Area Under the Plasma Concentration Time Curve From Time Zero to Infinite Time (AUCinf) of Carboplatin (Total and Free)","type":"SECONDARY","unitOfMeasure":"ng*hr/mL"}